Synbio Cannabinoids vs. Plant Extracts: Who Wins by 2035?

August 25, 2026

Photo by Mrdidg via Pixabay.

Two years ago the trajectory looked almost boringly predictable. Fermentation-derived CBG and CBC were going to do to plant extraction what recombinant insulin did to pancreas-derived insulin in the 1980s: take a scarce, labor-intensive biological product and make it in steel tanks, cheaper, at a scale agriculture can't touch. The economics were straightforward enough that you didn't need to be a synthetic biologist to see where the money was flowing. Then the December 2025 continuing resolution landed, and buried inside it was Section 781, a hemp redefinition that threatens to classify a molecule identical at the atomic level to plant-derived CBG or CBC as a federally controlled substance, purely because of where it came from.

That's a strange thing for a regulatory system to do, and it's worth sitting with why. American drug law has, for the better part of a century, drawn its lines around what a molecule is and how much of it is present, not around the industrial process that produced it. Section 781 breaks that pattern, at least on its current text, and in doing so it turns what looked like a settled cost question into an unsettled legal one. So the real question heading toward 2035 isn't simply which production method is cheaper. It's which one is legal, under which agency's reading, for how long, and what happens to the capital and cultivation decisions being made right now under that cloud of ambiguity.

How We Got Here: The Economic Case for Biosynthesis

Photo by Artem Podrez via Pexels.

The economic logic for biosynthesis was never subtle. Most cannabis chemovars express CBG, CBC, and CBN at well under 1% of dry weight, which means a processor extracting minor cannabinoids from biomass is paying for the acreage, water, labor, and drying costs of an entire plant to harvest a sliver of the compound they actually want. THC and CBD get the agronomic attention because they're present in double-digit percentages; everything else is a byproduct economy, and byproduct economies are expensive per gram almost by definition.

Precision fermentation offered an obvious way around that. Engineer a strain of yeast or algae to express the cannabinoid synthase enzymes that cannabis itself uses, feed it a cheap carbon source, and you get the target molecule without acreage, without seasonality, without the year-to-year agronomic variability that makes plant-based supply chains hard to forecast. This is the same basic playbook that gave the industry recombinant insulin and microbial rennet decades ago, and more recently it's the playbook behind fermentation-derived vanillin and Cargill's rebaudioside M, the stevia sweetener that used to require enormous leaf harvests and now comes largely from engineered yeast. In both of those cases, fermentation didn't just match the plant-derived cost curve -- it eventually undercut it, because industrial fermentation scales in a way farming structurally can't.

Cannabis biosynthesis companies built their business cases on exactly that precedent. If you can produce CBG or CBC at fermentation scale without needing a single acre of cannabis cultivation, you sidestep not just the yield problem but the cultivation licensing, land use, and crop risk that plant-derived processors carry as fixed costs. That was the pitch investors were buying into as recently as 2023 and 2024: minor cannabinoids were going to become commodity ingredients priced like industrial biochemicals, not boutique plant extracts. Nothing about the chemistry has changed since then. What's changed is whether the law will let that cost advantage actually reach the market.

Section 781: The Law That Changed the Trajectory

Photo by Miguel Acosta via Pexels.

The provision at the center of this is Section 781 of the December 2025 continuing resolution, which rewrote the federal statutory definition of hemp. The core move is this: any cannabinoid not naturally produced by the cannabis plant, or synthesized or manufactured outside the plant, falls outside the hemp definition and gets treated as a controlled substance under federal law rather than as a hemp derivative. On its face, that reads like a straightforward crackdown on the delta-8 and delta-10 conversion products that have proliferated in gas stations and smoke shops since the 2018 Farm Bill left an opening for hemp-derived synthetics.

But the text goes further than that narrower target. It doesn't just exclude novel molecules the plant never makes. It also excludes cannabinoids that are chemically identical to compounds the plant does produce, if those cannabinoids were synthesized or manufactured outside the plant itself. That's the clause that pulls fermentation-derived CBG and CBC into the blast radius, because a yeast-fermented CBG molecule and a plant-extracted CBG molecule are, by any chemical test available, the same compound. Section 781 doesn't ask what the molecule is. It asks where it came from.

The statute doesn't define synthesized or manufactured, and that omission is doing a lot of unplanned work right now. Does a fermentation process that uses engineered yeast to run the same enzymatic conversion the plant runs internally count as synthesis, or as biological production of a natural product? Nobody in a position of federal authority has answered that yet, and the effective dates for enforcement have themselves been shifting, which is its own tell. When an agency or Congress leaves an implementation date unsettled, it's usually because the underlying policy is still being fought over by people with enough leverage to slow it down -- in this case, hemp trade groups and biotech firms who have every incentive to push for a narrower reading before enforcement machinery spins up.

The Ambiguity Problem: Molecule Identity vs. Manufacturing Process

Photo by Tingey Injury Law Firm via Unsplash.

It helps to notice how unusual this regulatory approach actually is by historical standards. The line U.S. law has drawn around cannabis and hemp since 2018 has consistently been a molecule-and-concentration test: is the delta-9 THC content of the plant material above or below 0.3% dry weight. That test doesn't care how the plant was grown, bred, or processed. Section 781 is the first time federal hemp law has tried to regulate based on production pathway rather than the chemical identity of the end product, and that's a meaningfully different kind of legal claim to defend.

There's a useful precedent in how the FDA eventually handled nature-identical flavor and fragrance compounds. Fermentation-derived vanillin, chemically indistinguishable from vanillin extracted from vanilla beans, spent years in a regulatory gray zone before agencies and industry worked out labeling and identity standards that treated it as the equivalent product it chemically is. That resolution didn't happen overnight -- it took sustained rulemaking petitions, industry lobbying, and in some cases litigation before the identical-molecule argument won out over the production-method distinction. The parallel isn't perfect, since cannabinoids sit inside a controlled-substances framework that food flavoring never did, but the underlying legal question is structurally similar: can a regulator treat two atomically identical compounds as legally distinct because of how they were made?

Expect biosynthesis companies to make exactly this argument to the DEA, in comment periods, and potentially in court: a molecule with an identical structure, identical pharmacology, and identical safety profile cannot be treated as a separate controlled substance simply because it emerged from a bioreactor instead of a plant cell. That argument has real teeth, and it echoes disputes generic drug manufacturers have had for decades over bioequivalence standards. But teeth don't mean speed. Until this is resolved -- through agency guidance, litigation, or a future farm bill amendment that clarifies the definitional language -- fermentation-derived CBG and CBC occupy a genuine gray zone, chemistry notwithstanding.

What Plant-Derived Cultivators Gain in the Meantime

Ambiguity at the federal level doesn't just sit there neutrally. It changes incentives, and right now it's changing them in favor of the plant. If a processor or retailer can't get a clean answer on whether a fermentation-derived cannabinoid is legally hemp, the safer commercial move is to source the same compound from cannabis biomass, even at a cost premium, because at least that supply chain is unambiguously compliant under any plausible reading of Section 781.

That shift is reinforced by real progress in cannabis breeding. Cultivars have already been developed that suppress the enzyme responsible for converting CBGA into THCA or CBDA, effectively locking the plant's cannabinoid output at the CBG stage. Some of these high-CBG lines now express CBG at 15-20% of dry flower weight, compared to the sub-1% levels typical of unmodified chemovars. That's not fermentation-scale efficiency, but it's a genuine narrowing of the yield gap that used to make plant extraction look hopelessly uncompetitive on a per-gram basis. Breeding programs chasing high-CBC and high-CBN expression are following the same logic, though they're generally a few years behind the CBG work.

The bigger asset plant-derived cultivators have right now isn't cost -- it's certainty. A minor cannabinoid extracted from cannabis flower is unambiguously a hemp product under every reading of Section 781 currently in circulation, synthesized-outside-the-plant clause included. For a retailer or brand thinking about liability exposure, that certainty is worth paying for, especially in a period where nobody can tell them with confidence whether the fermentation-derived alternative sitting next to it on the shelf might get reclassified as a controlled substance next year. This is a case where regulatory clarity, not raw production economics, looks likely to be the deciding competitive variable through at least the early 2030s -- a reversal of the pure cost-curve story that dominated industry thinking just two years ago.

Projecting to 2035: Three Scenarios

Photo by Ivan S via Pexels.

Running this forward to 2035 means holding at least three plausible paths, none of which comes with a fixed date attached, because all of them depend on how contested legal language eventually gets resolved rather than on any predictable technology timeline.

The first scenario has regulators or courts eventually accepting that an identical molecule can't be treated as a different controlled substance based on its manufacturing origin, following roughly the same path nature-identical flavor compounds took toward normalization. If that ruling comes -- whether through DEA guidance, a court decision, or a farm bill rewrite -- the underlying cost advantage of fermentation reasserts itself fairly quickly, plausibly within five to seven years of that clarification, since the technology itself isn't the bottleneck. The second scenario has Section 781 holding essentially as written, with synthesized-outside-the-plant cannabinoids staying excluded from the hemp definition indefinitely. In that world, plant-derived minor cannabinoids remain the only federally low-risk supply chain straight through 2035, regardless of what fermentation can theoretically deliver on cost, because no processor wants to build a business on a controlled-substance classification risk.

The third scenario is a hybrid, and it's arguably the most interesting one for where new business opportunity actually opens up. Novel cannabinoid analogs that don't occur in the plant at all -- molecules synthetic biology can produce that cannabis genetics simply can't -- get pushed fully into pharmaceutical and controlled-substance regulatory channels, where companies can patent them and pursue FDA drug approval pathways instead of competing in the commodity hemp market. Meanwhile, commodity-tier CBG and CBC stay plant-derived because that's the compliance-safe route, and biosynthesis firms redirect their fermentation platforms toward those higher-margin, legally distinct novel molecules rather than fighting head-on for a share of the CBG market. This isn't a stretch: it's the same divergence you'd expect from a biotech sector that discovers one commercial lane is legally contested and another, adjacent lane is wide open.

Layer state-level divergence on top of all three scenarios. States have already built meaningfully different THC and hemp enforcement regimes since the 2018 Farm Bill, and there's no strong reason to expect Section 781's aftermath to unify rather than fragment further. Each of these three paths is a reasoned extrapolation from current statutory ambiguity and historical regulatory precedent -- not a forecast with a date attached, and readers should treat any confident date-specific prediction about this space with real skepticism.

Who Should Watch This Closely

Photo by Rachel Claire via Pexels.

Cultivators who've invested in high-CBG or high-CBC breeding programs should read the current moment correctly: Section 781's ambiguity is a tailwind, not a moat. It's giving plant-derived minor cannabinoids a market advantage right now, but that advantage rests entirely on an unresolved legal question that could flip with a single piece of agency guidance or a favorable court ruling for the biosynthesis side. Treating that as permanent competitive insulation would be a mistake; treating it as a multi-year window to build brand and distribution relationships while the legal question sorts itself out is the more defensible strategy.

Biosynthesis companies face a sharper decision, and probably need to make it soon. One path is to spend the resources fighting for identical-molecule recognition, essentially arguing the vanillin precedent forward into cannabinoid law -- an expensive, multi-year effort with a real but uncertain payoff. The other path is to stop trying to compete head-on with plant-derived CBG and CBC altogether and redirect R&D toward novel cannabinoid analogs that were never going to be plant-legal in the first place, positioning those molecules for pharmaceutical development instead. Companies that try to straddle both paths risk under-resourcing each.

Retailers and brands sourcing minor cannabinoid ingredients have the most immediate practical exposure, and the least reason to wait for a court to sort it out. Carrying a federally ambiguous SKU creates liability well before any litigation resolves the underlying question -- distributors and retailers have historically borne enforcement risk in exactly this kind of gray zone, and an audit of where your CBG, CBC, or CBN inputs actually come from is cheap insurance against a much more expensive problem later.

The closest historical parallel worth studying is delta-8 THC after the 2018 Farm Bill. That statute's own ambiguity around hemp-derived synthetic cannabinoids didn't get resolved quickly or cleanly -- it produced years of state-by-state patchwork enforcement, inconsistent court rulings, and a market that fragmented state by state rather than converging on a single national standard. There's no strong reason to expect Section 781's disputes to resolve faster. If anything, the stakes are higher this time, since the compounds in question include commodity ingredients already embedded in a much larger consumer products market than delta-8 ever reached.

The technology question was settled a while ago. Fermentation platforms modeled on insulin, rennet, and stevia production can make cannabinoids cheaper and more consistently than a farm ever will -- that's not really in dispute among people who work in either industry. What's genuinely open by 2035 is whether U.S. law is going to let biosynthesis compete on those terms, or whether Section 781's process-based definition holds and keeps plant-derived extraction as the only compliance-safe route for commodity minor cannabinoids.

That makes this one of the rare cases in cannabis policy where the next two or three years of agency guidance, litigation, and possible farm bill amendments will matter more to the eventual outcome than anything happening in a lab. Nobody needs a scientific breakthrough to make fermentation-derived CBG viable at scale -- that work is largely done. What's missing is legal certainty, and history suggests that kind of certainty tends to arrive slowly, through the same grinding sequence of agency comment periods, state-level divergence, and court challenges that took years to sort out delta-8's status after 2018.

The more likely shape of the 2035 market, if the current statutory ambiguity persists even partially, is fragmentation rather than a clean winner. Plant-derived cannabinoids probably keep the compliance-safe commodity tier -- the CBG and CBC going into mainstream wellness products sold by retailers who can't afford ambiguous SKUs. Biosynthesis, meanwhile, likely gets pushed toward the molecules that were never going to be plant-legal anyway: novel analogs that pharmaceutical companies can patent, run through FDA pathways, and regulate entirely outside the hemp framework Section 781 just rewrote. That's not the clean cost-driven victory synthetic biology looked headed for two years ago, but it's a coherent outcome grounded in exactly the kind of regulatory pattern this industry has lived through before.